German Medical Institute
Prostate Cancer Patient Engagement & Outcomes Study
Using Aria to digitise longitudinal patient-reported outcomes across the prostate cancer treatment pathway.
- Research Area: Oncology
- Prospective Observational
- Validated ePROs
- Quality of Life
- Treatment Follow-up
Part of the Agora 3.0 programme
01
The Challenge
Prostate cancer treatment can affect multiple aspects of a patient's quality of life, including urinary symptoms, sexual function, bowel symptoms, energy and psychological wellbeing.
Understanding these changes requires more than information captured during occasional clinical appointments. The Agora 3.0 project sought to create a more continuous, patient-centred approach in which patients could report symptoms and quality-of-life outcomes throughout treatment and follow-up, while giving clinicians structured data to support their review.
A broader objective of the project was to explore how digital tools could improve patient understanding and engagement with their own health information and strengthen communication between patients and their care teams.
02
The Study
Working with the German Medical Institute, Aria supported a prostate cancer study following patients across key stages of their treatment journey.
Participants completed established, validated patient-reported outcome measures assessing urinary symptoms, sexual function, prostate-cancer-specific quality of life and psychological wellbeing. These included:
- EPIC-CP
- Prostate-cancer-related quality of life across urinary, bowel, sexual and vitality/hormonal domains. The validated scoring produces five domain scores and an overall prostate cancer quality-of-life score.
- IPSS
- Severity of lower urinary tract symptoms using the International Prostate Symptom Score.
- IIEF-5
- Erectile function.
- HADS
- Anxiety and depression.
Data was collected longitudinally at defined points including baseline, post-treatment and follow-up, rather than relying on a single snapshot of the patient's experience.
The study design also incorporated a clinical nomogram to support estimation of recurrence risk and investigated how access to structured health information could affect patient empowerment and anxiety.
03
Aria Enabled
Multilingual study delivery
The study was delivered in both English and Greek, enabling participants to complete study activities and validated questionnaires in their preferred language.
Personalised study schedules
Activities and questionnaires were scheduled according to each patient's treatment pathway rather than one fixed study calendar.
Validated ePRO collection
EPIC-CP, IPSS, IIEF-5 and HADS were digitised within My Aria, allowing patients to complete validated outcome measures remotely.
Automated scoring & structured results
Questionnaire responses were converted into clinically meaningful scores and presented as structured longitudinal data for researchers and clinicians.
Patient reminders & follow-up
Personalised reminders supported completion of required assessments throughout the treatment and follow-up period.
Research oversight
The Aria Research platform enabled the study team to monitor participant progress and access study data through a central research environment.
04
The Results
The Agora prostate cancer study successfully progressed from platform development through study launch, recruitment and longitudinal participant follow-up.
Participant recruitment was completed in Q2 2026, demonstrating Aria's ability to support the delivery of a longitudinal oncology study within a specialist clinical environment.
A
Interim Excellence Grade
As part of the wider EU co-funded Agora 3.0 programme, Aria’s implementation was independently evaluated through a review organised by the Cyprus Research and Innovation Foundation (RIF) and carried out by an EU-level expert evaluator. The project received an “A” grade for Excellence, with the evaluator specifically highlighting the quality of the My Aria platform and its digital implementation.
05
Why It Matters
Patient-reported outcomes are most valuable when they are captured throughout the patient journey — not only when the patient is sitting in front of a clinician.
Agora demonstrated how Aria can bring validated clinical questionnaires into a structured digital workflow, automate longitudinal follow-up and turn patient-reported information into research-ready data.
For research teams, this creates a scalable way to collect high-quality outcomes outside traditional study visits. For patients, it provides a more continuous way to contribute information about how treatment is affecting their everyday lives.
Planning a longitudinal health study?